About this Event
During the last three years, we have seen explosive growth in out-licensing of Chinese innovations to global biopharma companies.
l Hengrui Pharmaceuticals entered a $6.03B USD deal for GLP-1 portfolio out-licensed to Hercules CM Newco
l Genmab stepped forward by acquisition of ProfoundBio for $1.8B USD in cash
l Candid Therapeutics raised $370M capital and acquired 2 T-cell engager antibodies for autoimmune diseases from Vignette Bio and TRC004
l MSD acquired investigational B-cell depletion therapy, CN201, from Curon Biopharmaceutical for $700 M USD upfront and up to $600M USD in milestone payments
In the past year, we have continued to see a surge in out-licensing deals between Chinese biotech firms and global pharmaceutical companies, signaling the growing influence of China's innovation in the global life sciences market. These partnerships are fueled by groundbreaking scientific achievements from leading Chinese biotech companies. However, despite these notable strides, significant challenges remain, such as reimbursement hurdles, commercialization pathways, securing venture financing, and navigating global market entry. This year's conference aims to further accelerate industry growth by fostering collaboration and knowledge exchange among key stakeholders around the globe.
The conference will highlight key trends in the following areas:
l Biotech capital market outlook and investment opportunities in the US and Asia
l Licensing trends in 2024 among Asian and US Pharmaceutical and Biopharma companies
l Emerging trends in NewCo with an emphasis on recent successful cross-border partnerships
l Leading biotech company road show presentations
Senior executives from more than 600 public & private healthcare companies across the biopharmaceuticals and biotech sectors attended our previous event in 2024. More than 300 PE and VC investors from over 100 firms were also present. The conference is an ideal setting for networking with the senior executives of your potential partners. Company management teams and investors will be able to participate in one-on-one and small-group meetings through BFC Group.
Event Venue & Nearby Stays
125 3rd St, 125 3rd Street, San Francisco, United States
USD 0.00
